<?xml version="1.0" encoding="UTF-8"?>
<p>One solution to this problem is to imagine that a large insurer (e.g., Lloyds or Munich Re) can estimate the risk that a vaccine under development will not be needed, and then sell insurance which pays off when that (non)event occurs. (After all, Lloyds insured the prize offered by a company’s ad campaign against discovering the Loch Ness Monster) [
 <xref rid="B4-ijerph-14-01304" ref-type="bibr">4</xref>,
 <xref rid="B5-ijerph-14-01304" ref-type="bibr">5</xref>]. The cost of insurance could and would be built into the firm’s total cost, so it would charge higher prices to cover it—but then those higher prices would go not toward excessive profits but just to cover insurance costs.
</p>
